In vitro evaluation of the antibacterial potential and modification of antibiotic activity of the Eugenia uniflora L. essential oil in association with led lights

Pereira, Nara Luana Ferreira; Aquino, Pedro Éverson Alexandre de; Júnior, José G.A.S.; Cristo, Janyketchuly S.; Filho, Marcos A. Vieira; Moura, Flávio F.; Ferreira, Najla M.N.; Silva, Maria K.N.; Nascimento, Eloiza Maria do; Correia, Fabrina M.A.; Cunha, Francisco Assis Bezerra da; Boligon, Alexandra Augusti; Coutinho, Henrique Douglas Melo; Matias, Edinardo Fágner Ferreira; Guedes, Maria Izabel Florindo

doi:10.1016/j.micpath.2017.07.048

Cited by 24 publications

(15 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…54 together with our previously published data indicating aBL and aPDI to be synergistic with routinely used antibiotics 55 . The sequential use of sub-lethal aBL and or aPDI results in antibiotic MIC values reduction by 2-, and even 64-fold 55–58 . Although the photodynamic priming is a well-known phenomenon, the observed within the current study hypersusceptibility of aPDI/aBL tolerant isolate to doxycycline and gentamycin may not be termed simple “priming”.…”

Section: Discussionmentioning

confidence: 99%

Development of Staphylococcus aureus tolerance to antimicrobial photodynamic inactivation and antimicrobial blue light upon sub-lethal treatment

Rapacka-Zdończyk

Woźniak

Pierański

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Antimicrobial photodynamic inactivation (aPDI) and antimicrobial blue light (aBL) are considered low-risk treatments for the development of bacterial resistance and/or tolerance due to their multitargeted modes of action. In this study, we assessed the development of Staphylococcus aureus tolerance to these phototreatments. Reference S . aureus USA300 JE2 was subjected to 15 cycles of both sub-lethal aPDI (employing an exogenously administered photosensitizer (PS), i.e., rose Bengal (RB)) and sub-lethal aBL (employing endogenously produced photosensitizing compounds, i.e., porphyrins). We demonstrate substantial aPDI/aBL tolerance development and tolerance stability after 5 cycles of subculturing without aPDI/aBL exposure (the development of aPDI/aBL tolerance was also confirmed with the employment of clinical MRSA and MSSA strain as well as other representatives of Gram-positive microbes, i.e. Enterococcus faecium and Streptococcus agalactiae ). In addition, a rifampicin-resistant (RIF R ) mutant selection assay showed an increased mutation rate in S . aureus upon sub-lethal phototreatments, indicating that the increased aPDI/aBL tolerance may result from accumulated mutations. Moreover, qRT-PCR analysis following sub-lethal phototreatments demonstrated increased expression of umuC , which encodes stress-responsive error-prone DNA polymerase V, an enzyme that increases the rate of mutation. Employment of recA and umuC transposon S . aureus mutants confirmed SOS-induction dependence of the tolerance development. Interestingly, aPDI/aBL-tolerant S . aureus exhibited increased susceptibility to gentamicin (GEN) and doxycycline (DOX), supporting the hypothesis of genetic alterations induced by sub-lethal phototreatments. The obtained results indicate that S . aureus may develop stable tolerance to studied phototreatments upon sub-lethal aPDI/aBL exposure; thus, the risk of tolerance development should be considered significant when designing aPDI/aBL protocols for infection treatments in vitro and in clinical settings.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of Staphylococcus aureus tolerance to antimicrobial photodynamic inactivation and antimicrobial blue light upon sub-lethal treatment

Rapacka-Zdończyk

Woźniak

Pierański

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The authors concluded from their observation that it is possible to determine the importance of cAMP in antibiotic susceptibility and biofilm formation of E. coli by photo-manipulating the cellular cAMP level using BsPAC. Most recently, Pereira et al also reported the synergism between 470-nm aBL with ciprofloxacin or norfloxacin against E. coli and S. aureus (Pereira et al, 2017a; Pereira et al, 2017b). …”

Section: Synergism Of Antimicrobial Blue Light With Other Agentsmentioning

confidence: 98%

Antimicrobial blue light inactivation of pathogenic microbes: State of the art

Wang

et al. 2017

Drug Resistance Updates

223

192

View full text Add to dashboard Cite

As an innovative non-antibiotic approach, antimicrobial blue light in the spectrum of 400–470 nm has demonstrated its intrinsic antimicrobial properties resulting from the presence of endogenous photosensitizing chromophores in pathogenic microbes and, subsequently, its promise as a counteracter of antibiotic resistance. Since we published our last review of antimicrobial blue light in 2012, there have been a substantial number of new studies reported in this area. Here we provide an updated overview of the findings from the new studies over the past 5 years, including the efficacy of antimicrobial blue light inactivation of different microbes, its mechanism of action, synergism of antimicrobial blue light with other angents, its effect on host cells and tissues, the potential development of resistance to antimicrobial blue light by microbes, and a novel interstitial delivery approach of antimicrobial blue light. The potential new applications of antimicrobial blue light are also discussed.

show abstract

“…The aPDI method probably leads to downregulated expression of these genes and the consequent reduced colistin resistance (Boluki et al, 2017 ). Possible explanations for aPDI/antimicrobial synergy include the ability of singlet oxygen and hydroxyl radicals to influence cellular homeostasis, the synthesis of nucleic acids (DNA and RNA), the alkalization of the cytoplasm and even the depolarization of the membrane (Pereira et al, 2017b ). ROS can potentiate killing when antimicrobial agents such as ciprofloxacin, gentamycin, and fluoroquinolones are used (reported by the Brynildsen group in 2013; Brynildsen et al, 2013 ).…”

Section: Mechanisms Underlying Combined Apdi/antimicrobials Treatmentmentioning

confidence: 99%

Combined Antimicrobial Activity of Photodynamic Inactivation and Antimicrobials–State of the Art

Woźniak

Grinholc

2018

Front. Microbiol.

View full text Add to dashboard Cite

Antimicrobial photodynamic inactivation (aPDI) is a promising tool for the eradication of life-threatening pathogens with different profiles of resistance. This study presents the state-of-the-art published studies that have been dedicated to analyzing the bactericidal effects of combining aPDI and routinely applied antibiotics in in vitro (using biofilm and planktonic cultures) and in vivo experiments. Furthermore, the current paper reviews the methodology used to obtain the published data that describes the synergy between these antimicrobial approaches. The authors are convinced that even though the combined efficacy of aPDI and antimicrobials could be investigated with the wide range of methods, the use of a unified experimental methodology that is in agreement with antimicrobial susceptibility testing (AST) is required to investigate possible synergistic cooperation between aPDI and antimicrobials. Conclusions concerning the possible synergistic activity between the two treatments can be drawn only when appropriate assays are employed. It must be noticed that some of the described papers were just aimed at determination if combined treatments exert enhanced antibacterial outcome, without following the standard methodology to evaluate the synergistic effect, but in most of them (18 out of 27) authors indicated the existence of synergy between described antibacterial approaches. In general, the increase in bacterial inactivation was observed when both therapies were used in combination.

show abstract

In vitro evaluation of the antibacterial potential and modification of antibiotic activity of the Eugenia uniflora L. essential oil in association with led lights

Cited by 24 publications

References 21 publications

Development of Staphylococcus aureus tolerance to antimicrobial photodynamic inactivation and antimicrobial blue light upon sub-lethal treatment

Development of Staphylococcus aureus tolerance to antimicrobial photodynamic inactivation and antimicrobial blue light upon sub-lethal treatment

Antimicrobial blue light inactivation of pathogenic microbes: State of the art

Combined Antimicrobial Activity of Photodynamic Inactivation and Antimicrobials–State of the Art

Contact Info

Product

Resources

About